--- canonical_name: Aviptadil alternate_names: Vasoactive Intestinal Peptide, VIP, Synthetic VIP, Aviptadil Acetate, RLF-100, Zyesami canonical_topic: Aviptadil for Health & Longevity short_topic_lc: aviptadil creation_date: 2026-0912-1219 creator_ai_fullname: Opus 5 ep_keywords: VIP Receptor Agonists, Neuropeptides, Vasodilators --- # Aviptadil for Health & Longevity

Evidence Review created on 09/12/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5 **Also known as:** Vasoactive Intestinal Peptide, VIP, Synthetic VIP, Aviptadil Acetate, RLF-100, Zyesami ## Motivation Aviptadil is a laboratory-made copy of a small signalling molecule that the human body produces in nerve endings, in the gut, and — in especially high concentrations — in the lungs. This molecule relaxes smooth muscle, widens blood vessels and airways, and calms immune cells. Because the body breaks it down within moments, it is inactive when administered orally, and is instead given by intravenous infusion, by inhalation, or by injection directly into tissue. Interest in the molecule stretches back decades. It first reached pharmacies as one half of an injectable treatment for erectile dysfunction, and was later tested in inflamed, scarred, and high-pressure lung conditions. During the coronavirus pandemic it drew far wider attention as a possible rescue treatment for people whose lungs were failing, and the findings from that period remain contested. This review examines what the clinical record shows about aviptadil: how it works, which effects have been measured in people and with what reliability, what harms have been recorded, how it has been administered, and where the evidence is thin or disputed. It also examines how the compound reaches people outside approved medical channels. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section collects high-level commentary and narrative literature that frames aviptadil's therapeutic claims, its evidence base, and its commercial history. * [A negative trial for vasoactive intestinal peptide in COVID-19-associated acute hypoxaemic respiratory failure](https://pubmed.ncbi.nlm.nih.gov/37348523/) - Lee & Slutsky, 2023 Two critical-care physiologists explain why a biologically plausible lung-protective peptide failed on hard endpoints, and what the trial design does and does not exclude. * [Aviptadil in Acute Respiratory Distress Syndrome-Promise or Mirage?](https://pubmed.ncbi.nlm.nih.gov/41368453/) - Chanchalani, 2025 The most recent balanced appraisal, weighing consistent oxygenation and inflammatory signals against the absence of a survival effect in pooled randomised data. * [Anticipated pharmacological role of Aviptadil on COVID-19](https://pubmed.ncbi.nlm.nih.gov/34846667/) - Mukherjee et al., 2022 The fullest narrative account of the compound's receptor pharmacology, regulatory history, orphan designations and formulation, written before the definitive trial reported. * [A comprehensive history of injection therapy for erectile dysfunction, 1982-2023](https://pubmed.ncbi.nlm.nih.gov/38644056/) - Porst et al., 2024 Eyewitness history from the field's founders, placing the aviptadil-phentolamine combination among the injectable agents and comparing its side-effect profile with theirs. * [Aviptadil for COVID-19: A Case Study and Call to Action About the Challenges of Research During a Global Pandemic](https://pubmed.ncbi.nlm.nih.gov/36227034/) - Auld, 2022 An intensivist dissects how sponsor press releases, expanded access and underpowered trials interacted around this specific drug; essential context for reading company-funded aviptadil claims. None of the six priority expert platforms (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, Lifespan.io) has published content on aviptadil or on synthetic vasoactive intestinal peptide. This is unsurprising: the compound is an injectable or nebulised prescription peptide with no consumer-facing formulation, so it falls outside the supplement and lifestyle scope those platforms cover. ## Grokipedia * [Aviptadil](https://grokipedia.com/page/Aviptadil) A structured overview of the synthetic peptide covering its receptor pharmacology, bronchodilatory and vasodilatory actions, and its development across respiratory and urological indications. ## Examine No Examine article exists for aviptadil. Examine.com covers dietary supplements and nutrition compounds and does not typically cover prescription medications; aviptadil is an injectable or nebulised prescription peptide, so its absence is expected. ## ConsumerLab No ConsumerLab article exists for aviptadil. ConsumerLab tests retail supplements and consumer health products and does not typically cover prescription medications; aviptadil is available only as a prescription injectable or nebuliser solution. ## Systematic Reviews The pooled literature on aviptadil is thin, and the two qualifying papers below cover its two separate therapeutic lines. * [Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis](https://pubmed.ncbi.nlm.nih.gov/41368449/) - Udupa et al., 2025 Nine studies, 665 patients: pooled survival was no better than placebo, with consistent oxygenation and inflammatory-marker gains in uncontrolled series. * [Erectile dysfunction: a global review of intracavernosal injectables](https://pubmed.ncbi.nlm.nih.gov/30895359/) - Duncan et al., 2019 Comparative efficacy, discontinuation and adverse-event data across injectable agents, including the aviptadil-phentolamine combination and its regulatory footprint. Aviptadil's central trade-off is short-term lung benefit against infusion-related harm and cost. The claimed effect is represented above; the principal risk is only partly represented, because Duncan et al. pool harms for the erectile-dysfunction route only. No systematic review pools the harms of intravenous or inhaled aviptadil, and that side of the trade-off is therefore unrepresented in the pooled literature. ## Mechanism of Action Aviptadil is a synthetic copy of vasoactive intestinal peptide (VIP, a 28-amino-acid signalling peptide released by nerves and immune cells). It binds two G-protein-coupled receptors — VPAC1 and VPAC2 (cell-surface proteins that pass the signal inward) — with comparable affinity, and only weakly to the related pituitary adenylate cyclase receptor. Binding raises cyclic adenosine monophosphate (cAMP, an intracellular messenger) and activates protein kinase A, which relaxes vascular and airway smooth muscle and suppresses inflammatory gene transcription through NF-κB (nuclear factor kappa B, a master switch for inflammatory genes). The lung carries the body's densest concentration of these receptors, with VPAC1 most heavily expressed on alveolar type II cells — which manufacture surfactant and which the pandemic coronavirus infects. That distribution underpins the claim that aviptadil is specifically lung-protective rather than a generic vasodilator. In sarcoidosis (a disease that studs the lungs with inflammatory clumps), inhaled peptide reduced tumour necrosis factor alpha (TNF-α, a principal inflammatory signal) release from lung immune cells and raised regulatory T cells. Pharmacologically it is unforgiving. Plasma half-life is roughly one minute, metabolic clearance about 9 mL/kg/min. Degradation is enzymatic, chiefly by neutral endopeptidase (an enzyme that cuts peptides apart), rather than hepatic cytochrome P450 (the liver enzyme family that clears most drugs), so classical metabolic drug interactions are largely absent. Continuous infusion or repeated local dosing is obligatory. A competing reading holds that the observed effects are non-specific vasodilation and haemodynamic change, with inflammatory-marker shifts a consequence of recovery rather than its cause. ## Historical Context & Evolution Vasoactive intestinal peptide was isolated from porcine small intestine in 1970 by [Sami Said and Viktor Mutt](https://pubmed.ncbi.nlm.nih.gov/5450698/), who were hunting for a gut-derived vasodilator. Its first therapeutic career was urological rather than pulmonary: from the late 1980s the peptide was paired with phentolamine (an alpha-blocker that widens arteries) for injection into erectile tissue, reaching approval in New Zealand by April 2000 and in the United Kingdom that October under the brand Invicorp. That development was interrupted. In 1999 trials were placed on hold after brown-adipose-tissue proliferation appeared in rodents given a competitor's phentolamine product. The hold was lifted in 2000 and the product was marketed; independent [comparative toxicology of drug-induced rodent brown-fat tumours](https://pubmed.ncbi.nlm.nih.gov/24141031/) has since concluded that such findings do not indicate human cancer risk at therapeutic doses. Roughly a decade of commercial momentum was lost — a product, [its developer later said](https://pubmed.ncbi.nlm.nih.gov/21050351/), ahead of its time. The respiratory line ran in parallel. Orphan designations followed for acute respiratory distress syndrome (sudden, severe failure of oxygen transfer across the lung) in 2001 and for pulmonary arterial hypertension (raised blood pressure in the lung's arteries) in 2005, supported by single-dose inhalation studies and a four-week open study in sarcoidosis. The pandemic transformed the compound's profile. Repurposed as RLF-100 and Zyesami, it moved through expanded-access programmes, fast-track designation and several randomised trials in quick succession. What changed after 2022 was not the mechanism but the quality of the comparison: once large placebo-controlled data arrived, the early survival claims did not replicate. ## Expected Benefits ### High 🟩 🟩 🟩 #### Restoration of Erectile Function in Men Refractory to Standard Therapy Aviptadil is licensed for erectile dysfunction only in a fixed combination with phentolamine, injected into erectile tissue; aviptadil acts on the veno-occlusive mechanism that traps blood, phentolamine on arterial inflow. Double-blind registration trials reported erections adequate for intercourse in a large majority of men, including non-responders to other therapies ([Dinsmore & Wyllie, 2008](https://pubmed.ncbi.nlm.nih.gov/18485029/)), a review co-authored by the product developer's chief scientific officer. A 308-man tertiary-centre series confirmed usefulness in contemporary practice ([Al-Mitwalli et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40192471/)), though it was retrospective and used no validated questionnaire. **Magnitude:** Registration trials reported efficacy in at least 80% of men; in the 308-man series 59% resumed penetrative intercourse — 76% among those who had abandoned alprostadil because of pain, 36% among true alprostadil non-responders. ### Medium 🟩 🟩 #### Faster Recovery from Hospitalised COVID-19 Pneumonia with Inhaled Dosing A multicentre, double-blind, placebo-controlled trial randomised 80 hospitalised adults across nine centres to nebulised aviptadil or placebo on top of standard care ([Esendagli et al., 2025](https://pubmed.ncbi.nlm.nih.gov/39870064/)). Time to discharge, breathlessness score at day 7 and day-28 lung-scan improvement all favoured the peptide, with no withdrawals for side effects. The trial is small, single-country and sponsored by the manufacturer of the inhaled formulation; the primary endpoint was borderline and mortality was descriptive only. Published methodological criticisms have been answered by the investigators ([Esendagli, 2026](https://pubmed.ncbi.nlm.nih.gov/40652932/)). **Magnitude:** Mean time to discharge 7.8 ± 4.0 days versus 10 ± 5.0 days (p = 0.049; p is the chance of seeing a difference this large if the treatment did nothing); greater improvement in lung-scan damage score at day 28 (p = 0.028); deaths 5.1% versus 12.2%, not a powered comparison. ### Low 🟩 #### Improved Oxygenation in Severe Viral Lung Injury ⚠️ Conflicted Oxygenation improved within days in a sponsor-funded randomised trial ([Youssef et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36044317/)) and in uncontrolled series ([Sampley et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38510776/)), but the larger independently funded trial found no clinical translation ([Brown et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37348524/)). Net reading: a short-lived gas-exchange effect that does not carry through to recovery. **Magnitude:** Oxygenation ratio 142 versus 105 at day 3 in the high-flow-oxygen subgroup (p = 0.01); pulse-oximetry-to-oxygen-fraction ratio rose from 149 to 336 over three days in an uncontrolled series. #### Survival in Critical Respiratory Failure ⚠️ Conflicted The sponsor-funded trial reported doubled 60-day survival as a secondary endpoint ([Youssef et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36044317/)); the larger, independently funded trial found none ([Brown et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37348524/)). Pooling both leaves no advantage ([Udupa et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41368449/)). Net reading: no survival benefit is established. **Magnitude:** Odds ratio 2.0 (an odds ratio compares the chance of an outcome in one group against another; 1.0 means no difference), 95% confidence interval (the range within which the true value most likely sits) 1.1–3.9, in the sponsor trial; hazard ratio (the same comparison expressed as a rate over time) 1.04 (0.77–1.41) in the independent trial; pooled odds ratio 1.01 (0.72–1.42). #### Acute Pulmonary Vasodilation in Pulmonary Hypertension A single inhaled dose given during right-heart catheterisation produced selective widening of the lung's blood vessels, improved stroke volume and better mixed venous oxygen saturation in 20 patients, without affecting systemic blood pressure ([Leuchte et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18978135/)). The effect was modest, short-lived and uncontrolled, and no chronic-dosing trial followed. **Magnitude:** Six of 20 patients achieved a fall in pulmonary vascular resistance greater than 20%; the literature reports no sustained outcome figure for repeated dosing. #### Protection Against Induced Airway Narrowing in Asthma Inhaled peptide raised the histamine dose needed to narrow the airways of six asthmatic adults, but left resting airway tone unchanged and was far weaker than inhaled salbutamol ([Barnes & Dixon, 1984](https://pubmed.ncbi.nlm.nih.gov/6465669/)). A second double-blind crossover study found the same against drug-induced narrowing ([Crimi et al., 1988](https://pubmed.ncbi.nlm.nih.gov/2971708/)). Both were tiny. **Magnitude:** The histamine concentration needed to narrow the airways rose from 2.18 to 5.00 mg/mL (p < 0.05), against 1.71 to 15.6 mg/mL for salbutamol; no trial has measured symptom or flare-up outcomes. ### Speculative 🟨 #### Suppression of Inflammatory Cytokine Release Placebo recipients showed a five-fold greater rise in interleukin-6 (an inflammatory messenger) than treated patients by day 7 ([Youssef et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36044317/)). Interleukin-6 is prognostic, not a validated target, so this is a biomarker finding. #### Immune Regulation in Sarcoidosis Four weeks of nebulised peptide lowered tumour necrosis factor alpha release from lung-lavage cells and raised regulatory T cells in 20 sarcoidosis patients ([Prasse et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20442436/)). Open-label, uncontrolled and biomarker-only, with no clinical endpoint. #### Restoration of Neuropeptide Signalling in Chronic Inflammatory Illness Compounded nasal-spray protocols claim restored regulatory signalling in biotoxin-related chronic inflammatory illness. No controlled trial is indexed on PubMed; the basis is practitioner case experience and mechanistic reasoning alone. ## Benefit-Modifying Factors * **Baseline severity of respiratory failure:** The sponsor trial's clearest signals sat in the high-flow-oxygen stratum rather than in already-ventilated patients, while the independent trial found no interaction with severity. Earlier intervention plausibly matters more than dose. * **Baseline inflammatory markers:** Treated patients whose interleukin-6 failed to rise by day 7 were far likelier to reach the trial's recovery endpoint, making baseline and day-7 inflammatory load the best-described response modifier available. * **Cause of erectile dysfunction:** Aviptadil's veno-occlusive action helps most where venous leak dominates. Men who had merely abandoned alprostadil for pain responded roughly twice as often as men who genuinely failed maximal alprostadil, where arterial insufficiency dominates. * **Genetic variation in the peptide's own pathway:** Sequence alterations in the human *VIP* gene have been described in idiopathic pulmonary arterial hypertension ([Haberl et al., 2007](https://pubmed.ncbi.nlm.nih.gov/17003842/)), raising the possibility that deficiency states respond differently from normal-signalling states. No pharmacogenetic testing is validated. * **Sex:** The intracavernosal indication is male-only. In the intravenous respiratory trials women made up 34–39% of participants, and no sex-based difference in benefit has been reported, though neither trial was powered to detect one. * **Pre-existing lung architecture:** Inhaled dosing tended to improve oxygenation specifically in patients with significant underlying lung disease, suggesting delivery to injured, poorly ventilated regions rather than systemic effect drives the response. * **Age:** Trial populations averaged 56–57 years, and the largest erectile-dysfunction series was in older referral patients. No age-stratified efficacy analysis exists; at the older end, arterial disease and slower recovery reduce expected gain. ## Potential Risks & Side Effects ### High 🟥 🟥 🟥 #### Vasodilatory Flushing, Headache and Dizziness Facial and truncal flushing follows from the peptide's action on vascular smooth muscle and is the most frequently recorded adverse event on every route. It was the commonest complaint in a 308-man injection series ([Al-Mitwalli et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40192471/)), is a common reaction in the licensed product's information, and recurred in healthy volunteers given intravenous infusions ([Domschke et al., 1978](https://pubmed.ncbi.nlm.nih.gov/730072/)). Headache and dizziness share the mechanism at a lower labelled frequency. All are self-limiting and resolve on stopping, often with palpitations and tachycardia (a fast heart rate). **Magnitude:** Flushing in 22.5% (69 of 308) of men receiving intracavernosal injection, and labelled at up to 1 in 10 users of the licensed combination product; headache and dizziness are labelled at up to 1 in 100 users. ### Medium 🟥 🟥 #### Secretory Diarrhoea with Systemic Dosing Vasoactive intestinal peptide drives intestinal chloride and water secretion — the mechanism behind the watery-diarrhoea syndrome of peptide-secreting pancreatic tumours — so diarrhoea is an on-target consequence of systemic dosing rather than a toxicity. In the randomised intravenous trial it was the only adverse event differing significantly between arms and the main reason for dose adjustment ([Youssef et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36044317/)). It was mild to moderate, and nobody stopped treatment for it. Inhaled and intracavernosal routes do not produce it. **Magnitude:** 32.8% versus 1.5% on placebo (p < 0.0001); 6.9% of treated participants required a reduction in infusion rate. #### Prolonged or Painful Erection Any agent injected into erectile tissue can produce an erection that fails to subside; untreated ischaemic priapism (a persistent erection with trapped, deoxygenated blood) causes irreversible tissue damage within hours. The aviptadil-phentolamine combination carries a markedly lower rate than alprostadil-based injections, which is its principal clinical advantage ([Al-Mitwalli et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40192471/)). The licensed product classifies prolonged painful erection as rare. Risk rises sharply with sickle-cell disease, leukaemia and multiple myeloma. **Magnitude:** One ischaemic priapism among 308 men (0.3%); product labelling places prolonged painful erection at up to 1 in 1,000 exposures. #### Injection-Site Bruising, Haematoma and Penile Nodules Repeated intracavernosal injection produces bruising and blood collection under the skin in a substantial minority, and small fibrous nodules along the shaft with prolonged use. A systematic review of injectable erectile-dysfunction therapies found adverse events in up to 26% of users and early discontinuation in up to 38%, most of it within three to six months of starting ([Duncan et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30895359/)). Injection anxiety, reported in roughly two-thirds of first-time users, compounds this. **Magnitude:** Adverse events in up to 26% and discontinuation in up to 38% of intracavernosal injection users; bruising is labelled as affecting up to 1 in 10. ### Low 🟥 #### Infusion-Related Hypotension ⚠️ Conflicted Blood-pressure falls occurred in about a quarter of infused patients, but at a similar rate on placebo, and none stopped treatment ([Youssef et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36044317/)); inhaled dosing left systemic pressure untouched ([Leuchte et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18978135/)). Net reading: real but usually transient, and hard to separate from critical illness itself. **Magnitude:** 26.0% versus 21.5% on placebo (p = 0.6), with resolution typically within about ten minutes of stopping the infusion. #### Excess Serious Adverse Events in Critical Illness ⚠️ Conflicted The composite of death, serious adverse events, organ failure, serious infection or grade 3–4 events by day 5 ran numerically higher on drug ([Brown et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37348524/)), while the sponsor trial recorded none attributable ([Youssef et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36044317/)). Net reading: an unresolved signal, not demonstrated harm. **Magnitude:** 63% (146 of 231) versus 56% (129 of 230), odds ratio 1.40 (95% confidence interval 0.94–2.08, p = 0.10). #### Cardiac Events with Intracavernosal Use Angina, chest pain and myocardial infarction (heart attack) appear in the licensed product's labelling as very rare reactions, reflecting post-marketing reports rather than trial data ([Porst et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38644056/)). The signal is confounded by the cardiovascular demand of intercourse in an older, vascular-disease-prone population. **Magnitude:** Labelled as affecting up to 1 in 10,000 users; no controlled trial has estimated an attributable rate. ### Speculative 🟨 #### Proliferative Signalling with Chronic Exposure Receptors for this peptide are overexpressed in prostate and breast tumours, so sustained stimulation is a theoretical growth concern. No human data address chronic dosing; the basis is receptor biology and isolated laboratory work only. #### Contaminants and Dose Error in Unregulated Product Research-grade peptide sold outside pharmacy channels is not tested for sterility or bacterial endotoxin, and purity certificates address identity rather than safety. No outcome data exist; the concern is documented for the grey peptide market. ## Risk-Modifying Factors * **Haemoglobin disorders:** Sickle-cell anaemia or trait, leukaemia and multiple myeloma all raise the chance that an induced erection will not subside. The licensed product treats all three as absolute bars to intracavernosal use. * **Baseline coagulation status:** Anticoagulant therapy is a labelled contraindication for intracavernosal use because of bleeding into erectile tissue. Platelet count and clotting time therefore modify injection-site risk more than they modify systemic risk. * **Baseline blood pressure and vasopressor requirement:** Patients already hypotensive or on multiple vasopressors (drugs given to raise blood pressure) have the least reserve for further vasodilation; one platform trial excluded anyone on three or more vasopressors. * **Sex:** The intracavernosal route and its entire risk profile — priapism, nodules, injection-site haematoma — apply to men only. Systemic risks apply to both sexes, with no reported sex difference. * **Pre-existing cardiovascular disease:** Ischaemic heart disease, prior stroke and heart failure raise the consequence of vasodilation and of sexual exertion; one trial excluded ejection fraction below 25% and unstable angina. * **Penile anatomy:** Peyronie's disease (fibrous scar plaques that curve the penis), cavernosal fibrosis and penile implants are labelled contraindications, since injection into scarred or prosthetic tissue risks poor distribution and injury. * **Age and autonomic reserve:** Older adults, particularly those with autonomic neuropathy (nerve damage affecting blood-pressure control) or orthostatic intolerance (dizziness on standing), tolerate vasodilatory drops less well, and their baseline flushing and palpitation burden is higher. ## Key Interactions & Contraindications * **Anticoagulants (warfarin, heparin, dabigatran, rivaroxaban, apixaban):** Absolute contraindication for intracavernosal use. Consequence: bleeding and haematoma into erectile tissue. No dose adjustment mitigates this; an alternative route or therapy is required. * **Other erectile-dysfunction drugs, including PDE5 inhibitors (phosphodiesterase type 5 inhibitors, the standard oral erection tablets — sildenafil, tadalafil) and injectables (alprostadil, papaverine):** Contraindicated concurrently. Consequence: additive vasodilation and priapism. Mitigation is temporal separation, not co-administration. * **Nitrates and nitric-oxide donors (drugs that release the vessel-relaxing signal nitric oxide — glyceryl trinitrate, isosorbide mononitrate):** Caution, and avoid with systemic infusion. Consequence: additive hypotension. Mitigation: hold nitrates during infusion and monitor blood pressure continuously. * **Antihypertensives and vasodilators (alpha-blockers such as doxazosin, calcium-channel blockers that relax artery walls such as amlodipine, diuretics that increase urine output):** Caution during infusion. Consequence: symptomatic hypotension. Mitigation: reduce or hold the antihypertensive and titrate the infusion rate downward. * **Neprilysin inhibitors (drugs that block neutral endopeptidase, the enzyme clearing this peptide — sacubitril/valsartan):** Monitor. Consequence: prolonged and amplified exposure. Mitigation: start at the lowest infusion rate with closer haemodynamic observation. * **Over-the-counter analgesics and antiplatelets (drugs that make platelets less sticky — aspirin, ibuprofen, naproxen):** Caution with the injectable route. Consequence: more injection-site bruising and haematoma. Mitigation: compress the site for five minutes and avoid visible veins. * **Over-the-counter decongestants (pseudoephedrine, phenylephrine):** Monitor. Consequence: opposing vasoconstriction plus tachycardia, blunting effect while adding cardiac strain. Mitigation: separate dosing from injection by several hours. * **Vasodilatory supplements (L-Arginine, L-Citrulline, beetroot nitrate, *Ginkgo biloba*, yohimbine):** Caution. These share aviptadil's vasodilatory and erectile-facilitating target and add to flushing, hypotension and priapism risk. Mitigation: discontinue before injection or infusion. * **Supplements affecting bleeding (fish oil, nattokinase, high-dose vitamin E, *Curcuma longa* extract):** Caution with injection. Consequence: increased injection-site haematoma. Mitigation: pause for seven days before starting self-injection training. * **Other interventions (vacuum erection devices, penile prosthesis, nebulised prostacyclin analogues — inhaled drugs that widen lung blood vessels):** A prosthesis is an absolute bar to injection, risking device damage. Use vacuum devices sequentially, not simultaneously, to avoid priapism. Given together, inhaled vasodilators risk additive hypotension. **Populations who should avoid Aviptadil:** * Men with a penile implant, Peyronie's disease or cavernosal fibrosis (intracavernosal route) * People with sickle-cell anaemia or sickle-cell trait, leukaemia, or multiple myeloma * People taking any oral or injectable anticoagulant (intracavernosal route) * People for whom sexual activity is medically inadvisable, including recent myocardial infarction (under 90 days) or unstable angina * People with heart failure and left ventricular ejection fraction below 25%, or on three or more vasopressors (systemic route) * People with known hypersensitivity to aviptadil or phentolamine mesilate * Children and adolescents under 18 years * Pregnant or breastfeeding women outside a supervised protocol, since exposure data are limited to isolated case reports ## Risk Mitigation Strategies * **Supervise the first injection:** The first intracavernosal dose is given in a nurse-led clinic with technique training and a six-week telephone follow-up, which is how the largest series kept priapism to one case in 308 men. * **Cap injection frequency:** No more than one injection per day and no more than three per week, as labelled. This limits cumulative fibrosis, penile nodule formation and injection-site haematoma. * **Set an explicit priapism escalation rule:** Any erection lasting beyond four hours requires immediate emergency presentation. Delay past roughly six hours is what converts a reversible event into permanent erectile tissue damage. * **Escalate systemic dosing stepwise:** Trials ramped over three days rather than starting at target. Stepwise escalation surfaces diarrhoea and hypotension at a dose that can still be reduced rather than abandoned. * **Reduce infusion rate rather than stop for diarrhoea:** Roughly 7% of infused patients needed a rate reduction; this kept mild-to-moderate diarrhoea tolerable without losing the treatment course. * **Monitor blood pressure continuously during infusion:** Falls occur in about a quarter of patients and typically resolve within ten minutes of stopping, so continuous measurement converts a hazard into a manageable, self-limiting event. * **Avoid visible veins and compress the site:** Selecting the lateral shaft, avoiding visible vessels and applying five minutes of pressure directly reduces bruising and haematoma, the commonest injection-site complaints. * **Pause bleeding-risk agents before starting injections:** Stopping fish oil, high-dose vitamin E and non-essential antiplatelet agents for about seven days lowers injection-site haematoma risk during the training phase. * **Require documentation for any non-pharmacy product:** Insisting on a batch certificate covering identity, purity, sterility and endotoxin addresses the contamination and dose-error risk of research-grade peptide. ## Therapeutic Protocol * **Intravenous regimen for respiratory failure:** Three successive twelve-hour infusions at 50, then 100, then 150 pmol/kg/hour — 600, 1,200 and 1,800 pmol/kg per day — the schedule used in both randomised trials and the expanded-access programme. * **Inhaled regimen:** 100 µg nebulised three times daily for up to 14 days, the dose carried into the adaptive platform trial and comparable to the four-week sarcoidosis schedule. * **Intracavernosal regimen:** A single ampoule delivering 25 µg aviptadil with 2 mg phentolamine mesilate into the lateral shaft, maximum one injection daily and three weekly. * **Competing approaches:** Intravenous dosing targets systemic inflammation, inhaled dosing targets the alveolar surface at lower systemic exposure, intracavernosal dosing is purely local. None has been compared head-to-head. * **Compounded nasal route:** Functional-medicine protocols use compounded nasal spray, typically 50 µg per spray four times daily, escalating to 100 µg. This route has no controlled trial support. * **Who popularised each approach:** Jihad Georges Youssef at Houston Methodist and Jonathan Javitt at NeuroRx for intravenous use; Antje Prasse in Freiburg for inhaled use; David Ralph's unit at University College London Hospitals for injection. * **Best time of day:** Intracavernosal injection is given 10–15 minutes before intended activity. Infusions ran overnight in trials for monitoring convenience; no circadian advantage has been demonstrated for any route. * **Half-life:** Plasma half-life is roughly one minute, with clearance near 9 mL/kg/min. Nothing accumulates, and any systemic effect ends within minutes of stopping delivery. * **Single versus split dosing:** Splitting is mandatory, not optional. The one-minute half-life means only continuous infusion, thrice-daily nebulisation or immediately pre-activity injection can sustain receptor occupancy. * **Genetic factors in dose choice:** Sickle-cell trait or disease bars the injectable route outright rather than modifying dose. No validated pharmacogenetic marker guides infusion rate; *VIP* gene variants remain a research observation. * **Sex-based differences:** No dose adjustment by sex has been established for systemic routes, and trials did not stratify dosing. The intracavernosal regimen is male-specific by definition. * **Age-related adjustment:** No age-based dose reduction is specified, but older patients with lower vascular reserve are typically started at the lowest infusion rate and escalated more slowly. * **Baseline biomarkers guiding response:** Baseline oxygenation ratio and inflammatory markers were the covariates that predicted response in trials, and are the practical basis for deciding whether systemic dosing is worth starting. * **Pre-existing conditions shaping the regimen:** Venous-leak erectile dysfunction favours the injectable route; significant underlying lung disease favours inhaled delivery, which improved oxygenation preferentially in that group. ## Discontinuation & Cycling * **Short course by design:** Every studied systemic protocol is finite — three days intravenously, up to 14 days inhaled, four weeks nebulised in sarcoidosis. No protocol contemplates indefinite systemic use. * **On-demand use for the injectable route:** The intracavernosal combination is used episodically before activity, not continuously, so discontinuation means simply ceasing to use it. * **No withdrawal syndrome:** With a one-minute half-life and no receptor-downregulation data in humans, no withdrawal effects have been reported after stopping any route, including the four-week sarcoidosis course. * **No taper required:** Trials stopped infusions abruptly at the end of day three without a taper and reported no rebound. Oxygenation gains simply faded over the following days. * **Cycling not established:** No study has tested repeat courses or scheduled cycling. Whether a second course restores the transient gas-exchange effect is unknown, as is any risk from repetition. * **Effect fades rather than persists:** The short-term oxygenation advantage appeared to narrow after infusion ceased, which is why longer rather than cyclical treatment was proposed for future trials. ## Sourcing and Quality * **Licensed injectable product:** The only approved aviptadil-containing medicine is the fixed aviptadil-phentolamine ampoule, supplied refrigerated at 2–8 °C with matched syringes and needles. It is prescription-only and dispensed through pharmacies. * **No approved respiratory product:** Neither intravenous nor inhaled aviptadil holds marketing authorisation anywhere. Supply for those routes has come from trial sponsors, expanded-access programmes, or hospital-level import arrangements in India and Turkey. * **Compounding pharmacies:** Nasal-spray and injectable preparations are produced by compounding pharmacies including Strive Pharmacy and Wells Pharmacy Network. Compounded products are not subject to approval review and lack the efficacy and stability data of licensed medicines. * **What to look for:** A complete batch certificate of analysis covers identity, chromatographic purity, peptide content, sterility and bacterial endotoxin. Certificates limited to purity confirm identity only and say nothing about contamination. * **Research-grade supply:** Peptide sold as research-use-only is unapproved material not intended for human use. Testing, documentation and recall mechanisms are all voluntary in that market, and no purity threshold is enforced. * **Formulation and handling:** Aviptadil is a 28-amino-acid peptide that degrades rapidly once reconstituted and adsorbs to plastic. Cold-chain integrity and use within the labelled window after removal from refrigeration matter more than for small molecules. ## Practical Considerations * **Time to effect:** Effects are immediate. Erection follows injection within minutes; oxygenation changes appeared within one to three days of starting infusion; breathlessness scores separated from placebo by day 7 of nebulised dosing. * **Effects do not persist:** The commonest misreading is expecting durable benefit from a compound with a one-minute half-life. Gas-exchange gains narrowed once infusion stopped, and injectable use restores nothing between doses. * **Conflating the two therapeutic lines:** Evidence for the licensed erectile-dysfunction combination does not transfer to intravenous or inhaled aviptadil, and vice versa. The routes, doses and endpoints share only the molecule. * **Regulatory status:** Aviptadil is approved only as the fixed combination for erectile dysfunction, in a limited set of countries. Every respiratory use is investigational or off-label; fast-track designation is not approval. * **Cost and access:** The licensed combination costs several times generic alprostadil per dose, and payers and formularies favour the cheaper agent by default. That structural cost incentive shapes which injectable appears in guidelines and gets studied. * **Access for respiratory use:** Outside a trial, intravenous or inhaled aviptadil is effectively unobtainable through normal channels in most countries, which is precisely what drives interested individuals toward compounded and research-grade supply. ## Interaction with Foundational Habits * **Sleep:** Indirect and mostly neutral. The peptide is a circadian signalling molecule in the brain's master clock, but with a one-minute plasma half-life no systemic sleep effect is plausible from peripheral dosing. Practical consideration: infusion-related flushing and palpitations can disturb overnight sleep; trials nonetheless ran infusions overnight for monitoring convenience. * **Nutrition:** Indirect. Systemic dosing causes intestinal water and electrolyte secretion, so diarrhoea during infusion warrants oral rehydration with sodium and potassium rather than plain water. Practical consideration: high-osmolarity supplements, magnesium salts and sugar alcohols compound the effect for as long as a course runs. * **Exercise:** Direct but transient. Acute pulmonary vasodilation improves stroke volume and mixed venous oxygen saturation, which in principle eases exertion in pulmonary hypertension, but the effect is too short-lived to alter training. Practical consideration: vigorous exercise immediately after intracavernosal injection adds cardiac demand while vasodilation is maximal. * **Stress management:** Indirect and potentiating. The peptide suppresses inflammatory transcription and expands regulatory T cells, overlapping with the anti-inflammatory effects of sleep, restraint of chronic stress and parasympathetic practices. Practical consideration: injection anxiety affects roughly two-thirds of first-time users and remains elevated for months, so desensitisation training measurably improves persistence. ## Monitoring Protocol & Defining Success Before any systemic course, baseline testing establishes whether vasodilation is safe and sets the comparators for later response: resting blood pressure and heart rate, oxygen saturation on room air, a full blood count with platelets, clotting time, serum sodium and potassium, and inflammatory markers. Where the injectable route is planned, a sickle-cell screen and clotting profile change eligibility rather than dosing, and total testosterone shows whether erectile dysfunction has a correctable hormonal component. Ongoing monitoring is dense during treatment and sparse afterwards: blood pressure and heart rate continuously throughout each infusion, oxygen saturation and oxygenation ratio daily on days 1 through 3, electrolytes on day 3 if diarrhoea occurs, inflammatory markers at days 3 and 7, and a clinical review at 4 weeks. Injectable users are reviewed at 6 weeks, then roughly every 3 months. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |---|---|---|---| | Systolic / diastolic blood pressure | 110–125 / 70–80 mmHg | Detects the commonest systemic effect | Measure continuously during infusion; a fall usually resolves within ten minutes of stopping | | Resting heart rate | 55–70 bpm | Tachycardia accompanies flushing | Paired with blood pressure; conventional clinical range is 60–100 bpm; palpitations are a stop signal on the labelled injectable product | | Oxygen saturation on room air | 95–99% | Tracks the main claimed respiratory effect | Fasting not required; measure at the same posture and activity level each time | | PaO₂/FiO₂ ratio | Above 300 | The endpoint on which trial benefit was claimed | PaO₂/FiO₂ means arterial oxygen pressure divided by inspired oxygen fraction; requires arterial sampling; conventional acute respiratory distress syndrome thresholds are 300, 200 and 100 for mild, moderate and severe | | High-sensitivity C-reactive protein (hs-CRP) | Below 0.5 mg/L | Anchors the anti-inflammatory claim | hs-CRP is a general marker of body-wide inflammation; conventional laboratories report below 3.0 mg/L as normal; draw fasting and not within two weeks of infection | | Interleukin-6 | No established treatment target; track the change from the individual's own day-0 value, since failure to rise by day 7 predicted recovery | The biomarker on which the sponsor trial rested | Not a validated surrogate endpoint; short half-life makes time-of-day consistency important | | Platelet count | 175–250 × 10⁹/L | Governs injection-site bleeding risk | Part of a full blood count; conventional laboratories report 150–400 × 10⁹/L as normal; repeat only if bruising is disproportionate | | Prothrombin time / INR | 0.9–1.1 | Anticoagulation bars the injectable route | INR means international normalised ratio, a measure of how fast blood clots; best paired with platelet count; any anticoagulant makes intracavernosal use contraindicated regardless of value | | Serum sodium | 137–142 mmol/L | Detects losses from secretory diarrhoea | Conventional laboratories report 135–145 mmol/L as normal; draw on day 3 of infusion if stool frequency rises; pair with potassium | | Serum potassium | 4.0–4.5 mmol/L | Diarrhoea depletes potassium fastest | Conventional laboratories report 3.5–5.1 mmol/L as normal; haemolysed samples read falsely high; redraw rather than act on an isolated result | | Total testosterone | 600–900 ng/dL | Identifies a correctable cause of erectile dysfunction | Conventional laboratories report 300–1000 ng/dL as normal; draw fasting before 10:00; pair with sex hormone binding globulin for a free estimate | | Haemoglobin electrophoresis (sickle-cell screen) | Negative for sickle haemoglobin | Sickle disease or trait bars injectable use | One-off baseline test; positivity is an absolute contraindication, not a dose modifier | Qualitative markers worth tracking alongside the laboratory values: * Breathlessness on a standardised exertion scale, which separated from placebo by day 7 in the inhaled trial * Flushing frequency and intensity, the earliest sign that dosing is at or above the vasodilatory threshold * Stool frequency and consistency during systemic courses * Energy and exercise tolerance in the weeks after a course, which is where fading of effect first becomes apparent * For the injectable route, satisfaction with rigidity and duration, plus any penile pain or palpable nodules * Injection-related anxiety, which drives most early discontinuation ## Emerging Research * **No aviptadil trial is currently recruiting:** As of September 2026 ClinicalTrials.gov lists eight studies naming aviptadil as an intervention; seven are completed, terminated or withdrawn, and the eighth is active but no longer enrolling. The evidence base is therefore closed rather than maturing, which is itself the most important fact about the field. * **Adaptive platform data still to report:** I-SPY COVID ([NCT04488081](https://clinicaltrials.gov/study/NCT04488081)), a 1,500-participant phase 2 platform trial, ran a nebulised 100 µg three-times-daily arm. That arm is closed, but the platform remains active with estimated primary completion in 2028, so comparative data may still emerge. * **Full independent dataset not yet exhausted:** The independently funded trial ([NCT04843761](https://clinicaltrials.gov/study/NCT04843761)) stopped for futility and reported no benefit at day 90 ([Brown et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37348524/)). Its biomarker and subgroup analyses could still clarify whether an earlier-treatment window exists. * **Inhaled route is the live hypothesis:** The Turkish inhaled trial ([NCT04844580](https://clinicaltrials.gov/study/NCT04844580)) reported faster discharge and better lung-scan recovery ([Esendagli et al., 2025](https://pubmed.ncbi.nlm.nih.gov/39870064/)). Whether this survives replication with lower systemic exposure would strengthen or collapse the case. * **A terminated European trial left a gap:** The Swiss inhaled study in patients at high risk of respiratory distress ([NCT04536350](https://clinicaltrials.gov/study/NCT04536350)) closed after 83 participants. Its published protocol ([Boesing et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36127739/)) defines the early-intervention question nobody has since answered. * **Post-viral lung injury is proposed but untested:** Commentators argue for inhaled dosing in persistent post-infection lung damage rather than acute failure ([Charles et al., 2026](https://pubmed.ncbi.nlm.nih.gov/40675136/)). No trial has been registered for that indication. * **Erectile-dysfunction evidence remains uncontrolled:** No randomised trial of the aviptadil-phentolamine injection is currently registered; the largest modern dataset is retrospective and lacks validated instruments ([Al-Mitwalli et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40192471/)). A controlled comparison against alprostadil would settle the pain-and-priapism advantage. * **Immune indications have not advanced:** The sarcoidosis signal ([Prasse et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20442436/)) has produced no controlled follow-up in 16 years, despite being the only human demonstration of the peptide's immunoregulatory effect. ## Conclusion Aviptadil is a synthetic copy of a natural signalling molecule that relaxes blood vessels and airways and quietens immune cells, with its densest receptor population in the lung. It exists in two almost separate worlds. In one, combined with a second drug and injected locally, it restores erections in men who cannot use or have failed other treatments, with less pain and far less risk of a prolonged erection than the standard alternative. That use is licensed in a few countries and rests on the strongest evidence the compound has, although the key supporting review was written in part by the company that developed it. In the other, given by intravenous infusion or inhalation for failing lungs, it produces quick and reproducible improvements in oxygen transfer and in inflammation markers. With infusion those gains did not carry through to survival or recovery, and pooling everything leaves no advantage; with inhalation one small trial reported faster recovery, so far unrepeated. Much of the encouraging work was funded by the companies developing it, and the larger publicly funded trial found nothing. The harms are mostly predictable extensions of what the molecule does: flushing, diarrhoea with systemic dosing, bruising and rare prolonged erections with injection. Nothing accumulates, because the body clears it within about a minute — which is also why every effect stops when dosing stops. For anyone weighing it, the honest reading is a well-characterised local treatment and an unresolved systemic one, with no product for the latter outside research channels. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**